Evaluation of chromosome 1p/19q deletion by Fluorescence in Situ Hybridization (FISH) as prognostic factors in malignant glioma patients on treatment with alkylating chemotherapy

被引:2
|
作者
Pandith, Arshad A. [1 ,7 ]
Zahoor, Wani [1 ]
Manzoor, Usma [1 ]
Nisar, Syed [2 ]
Guru, Faisal R. [2 ]
Naikoo, Niyaz A. [3 ]
ul Aein, Qurat [1 ]
Baba, Shahid M. [1 ]
Bhat, Abdul R. [4 ]
Ganai, Farooq [5 ]
Shah, Parveen [6 ]
机构
[1] Sher I Kashmir Inst Med Sci SKIMS, Adv Ctr Human Genet, Srinagar, J&k, India
[2] Sher I Kashmir Inst Med Sci SKIMS, Dept Med Oncol, Srinagar, J&K, India
[3] Cluster Univ, Higher Educ Dept, Dept Biotechnol, Srinagar, J&K, India
[4] Sher I Kashmir Inst Med Sci SKIMS, Dept Neurosurg, Srinagar, India
[5] Sher I Kashmir Inst Med Sci SKIMS, Dept CVTS, Srinagar, J&K, India
[6] SKIMS, Dept Pathol, Srinagar, J&K, India
[7] Sher I Kashmir Inst Med Sci SKIMS, Adv Ctr Human Genet, Srinagar, Kashmir, India
关键词
Glioma; Chromosome; 1p/19q; Glioblastoma; Co-deletion; Astrocytoma; DIAGNOSED ANAPLASTIC OLIGODENDROGLIOMAS; PHASE-III TRIAL; ADJUVANT PROCARBAZINE; ADULT GLIOMA; 1P; TUMORS; 19Q; TEMOZOLOMIDE; SURVIVAL; OLIGOASTROCYTOMAS;
D O I
10.1016/j.cancergen.2023.08.005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Either deletion or co-deletion of chromosomal arms 1p or 19q is a characteristic and early genetic event in oligodendroglial tumors that is associated with a better prognosis and enhanced response to therapy. Information of 1p/19q status is now regarded as the standard of care when managing oligodendroglial tumors for therapeutic options in anticipation of the increased survival and progression-free survival times associated with it. Keeping this in view, we first time attempted to establish the FISH based detection of 1p/19q deletion in glioma tissue samples to evaluate its role and involvement in the disease.Method: Overall 39 glioma cases of different histologies were evaluated by fluorescence in situ hybridization (FISH) technique using specific FISH probes with Olympus BX43 fluorescent microscope to detect chromosomes 1p and 19q or co-deletions therein.Results: Of the 39 glioma samples, overall 27 (69.2%) were found to have deletion either in 1p, 19q or both. Deletions were observed in 23.0%, 7.6% and 38.4% in 1p, 19q and 1p/19q co-deletions respectively. Overall oligidendrioglioma presented with 53.8% (21 of 39) deletions, astrocytoma group showed 12.8% and GBM accounted for 2.5% deletions. Overall survival and disease free survival was seen significantly better in oligidendrioglioma and astrocytoma with deleted tumors as compared to non-deleted ones (p<0.05).Conclusion: Allelic losses on 1p and 19q, either discretely or shared, were more frequent in classic oligodendrogliomas than in either astrocytoma or Glioblastoma with better survival and response to therapy.
引用
收藏
页码:55 / 61
页数:7
相关论文
共 50 条
  • [41] Assessment of the 1p/19q Deletions at Different Areas in Biphasic Oligoastrocytomas by Using Chromogenic In Situ Hybridization
    Oliveira, V. C.
    Carrara, R. C. V.
    Covas, D. T.
    Latorraca, E. F.
    Carlotti, C. G.
    Colli, B. O.
    Machado, H. R.
    Neder, L.
    LABORATORY INVESTIGATION, 2009, 89 : 333A - 333A
  • [42] Assessment of the 1p/19q Deletions at Different Areas in Biphasic Oligoastrocytomas by Using Chromogenic In Situ Hybridization
    Oliveira, V. C.
    Carrara, R. C. V.
    Covas, D. T.
    Latorraca, E. F.
    Carlotti, C. G., Jr.
    Colli, Bo
    Machado, H. R.
    Neder, L.
    MODERN PATHOLOGY, 2009, 22 : 333A - 333A
  • [43] Prognostic value of 1p/19q rearrangement in oligodendrogliomas: Retrospective study with 86 patients
    Guegan, Y
    Auger, N
    Saikali, S
    Hamlat, A
    Laviolle, B
    Le Calve, M
    NEURO-ONCOLOGY, 2005, 7 (03) : 333 - 333
  • [44] Concomitant Deletion of Short Arm (del 1p) and Amplification or Gain (1q21) of Chromosome 1 By Fluorescence in Situ Hybridization (FISH) Is Associated with Poor Clinical Outcome
    Mohan, Meera
    Gong, Zimu
    Kendrick, Samantha
    Thanendrarajan, Sharmilan
    Schinke, Carolina
    Alapat, Daisy
    Tricot, Guido
    Zhan, Fenghuang
    van Rhee, Frits
    Sawyer, Jeffery R.
    Tian, Erming
    Zangari, Maurizio
    BLOOD, 2021, 138
  • [45] Characterizing the breakpoint of 1p/19q co-deletion in glioma with long-read sequence technology
    Sugawa, Masahiro
    Kimura, Keisuke
    Sakamoto, Yoshitaka
    Ochi, Yotaro
    Nakamura, Wataru
    Mateos, Raul
    Chiba, Kenichi
    Okada, Ai
    Okuda, Rurika
    Tsujimura, Taro
    Ohka, Fumiharu
    Motomura, Kazuya
    Kato, Motohiro
    Saito, Ryuta
    Ogawa, Seishi
    Shiraishi, Yuichi
    CANCER SCIENCE, 2025, 116 : 1115 - 1115
  • [46] Clinical relevance of 1p and 19q deletion for patients with WHO grade 2 and 3 gliomas
    Iwamoto, Fabio M.
    Nicolardi, Linda
    Demopoulos, Alexis
    Barbashina, Violetta
    Salazar, Paulo
    Rosenblum, Marc
    Hormigo, Adilia
    JOURNAL OF NEURO-ONCOLOGY, 2008, 88 (03) : 293 - 298
  • [47] Clinical relevance of 1p and 19q deletion for patients with WHO grade 2 and 3 gliomas
    Fabio M. Iwamoto
    Linda Nicolardi
    Alexis Demopoulos
    Violetta Barbashina
    Paulo Salazar
    Marc Rosenblum
    Adília Hormigo
    Journal of Neuro-Oncology, 2008, 88 : 293 - 298
  • [48] IDH-wildtype Glioblastoma with 1p/19q Co-deletion by FISH: An Important Clinical Pitfall
    Umphlett, Melissa
    Rashidipour, Omid
    Vij, Meenakshi
    Hadjipanayis, Constantinos
    Germano, Isabelle
    Houldsworth, Jane
    Crary, John
    Tsankova, Nadeja
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2022, 81 (06): : 458 - 459
  • [49] Chromosome 1p allelic loss by fluorescence in situ hybridization (FISH) not observed in dysembryoplastic neuroepithelial tumors.
    Prayson, RA
    Castilla, EA
    Hartke, M
    Tubbs, RR
    Barnett, GH
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2002, 61 (05): : 477 - 477
  • [50] ASSOCIATION BETWEEN FLUORESCENCE IN SITU HYBRIDISATION (FISH) PROBE RATIO SCORES AND SURVIVAL IN 1p/19q CO-DELETED GLIOMAS
    Pinkham, Mark
    McBain, Catherine
    DuPlessis, Daniel
    Telford, Nick
    O'Neill, Fran
    Gattamaneni, Rao
    Tran, Anna
    Whitfield, Gillian
    NEURO-ONCOLOGY, 2014, 16